GW treats p16 OPX with neoadjuvant chemo TORS /-adj RT(PMID: 38581118). 90% do not get RT due to low residual disease at surgery, & PFS >95% in these chemo-selected pts. Anecdotally, as main HN
#radonc at GW, I've seen these pts do well but more study is needed. Some thoughts🧵